Satellos Bioscience (TSE:MSCL) has released an update.
Satellos Bioscience has received approval to start a Phase 1 clinical trial in Australia for SAT-3247, a novel oral drug aimed at regenerating skeletal muscle in Duchenne muscular dystrophy (DMD) patients. The trial will assess the safety and pharmacokinetic properties of SAT-3247, first in 72 healthy volunteers and later in 10 DMD patients. This development marks an important step for Satellos, potentially offering a disease-modifying treatment for DMD irrespective of genetic mutation.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
